Precigen (PGEN) EBITDA Margin (2012 - 2026)
Precigen (PGEN) posted quarterly EBITDA Margin of 25.78% for Q1 2026, up 165923.0% year-over-year from N/an in Q1 2025, and up 90.64% quarter-over-quarter from 275.44% in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) EBITDA Margin (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported EBITDA Margin for 15 consecutive years, with 25.78% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 165923.0% year-over-year to 25.78%; the TTM figure through Mar 2026 stood at 285.94% (up 203125.0% YoY), while the FY2025 annual figure was 1141.13%, up 229910.0% from the prior year.
- EBITDA Margin grew to 25.78% in Q1 2026 per PGEN's latest filing, from 275.44% in the prior quarter.
- Across five years, EBITDA Margin topped out at 149.86% in Q4 2022 and bottomed at 2126200.0% in Q3 2024.
- Historically, EBITDA Margin has averaged 265392.52% across 5 years, with a median of 1440.13% in 2025.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 209364793 bps — and 2025, when it soared 212253960 bps.
- Precigen's EBITDA Margin stood at 149.86% in 2022, then slumped by 1960 bps to 2786.97% in 2023, then jumped by 72 bps to 772.79% in 2024, then soared by 64 bps to 275.44% in 2025, then jumped by 91 bps to 25.78% in 2026.
- Business Quant data shows PGEN's EBITDA Margin at 25.78% in Q1 2026, 275.44% in Q4 2025, and 3660.4% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 41.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.18% |
| Mar 31, 2026 | -25.78% |
| Dec 31, 2025 | -474.61% |
| Sep 30, 2025 | -1,180.05% |
| Jun 30, 2025 | -3,710.75% |
| Mar 31, 2025 | -1,685.01% |
| Dec 31, 2024 | -2,396.30% |
| Sep 30, 2024 | -2,231.06% |
| Jun 30, 2024 | -8,485.50% |
| Mar 31, 2024 | -2,292.02% |
| Dec 31, 2023 | -2,786.97% |
| Sep 30, 2023 | -1,518.27% |
| Jun 30, 2023 | -1,195.25% |
| Mar 31, 2023 | -1,268.40% |
| Dec 31, 2022 | -1,236.36% |
| Sep 30, 2022 | -45.53% |
| Jun 30, 2022 | -830.02% |
| Mar 31, 2022 | -401.83% |
| Dec 31, 2021 | -593.70% |
| Sep 30, 2021 | -645.96% |